Skip to content


Pediatric PBPK Scaling Model for a New Long-Acting, 3 HIV Drug Combination in a Single Injection (abstract CROI).  Perazzolo S, Stephens Z, Delle Fratte R, Bender-Ignacio R, Johnson C, Hartman M, Hanscom B, Collier AC, Melvin AJ, Ho RJY, Conference on Retroviruses and Opportunistic Infections (CROI), 2024.

[NEW ARTICLE!!] Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. Griffin JI, Chen X, Duan L, Mu Q, Ho RJY. PLOS ONE, published online 2024.

[NEW ARTICLE!!] Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products. Perazzolo S, Shen DD, Scott AM, Ho RJY. J Pharm Sci published online, 2024.

[NEW ARTICLE!!A novel formulation enabled transformation of 3-HIV drugs tenofovir–lamivudine–dolutegravir from short-acting to long-acting all-in-one injectable. Perazzolo S, Stephen ZR, Masa E, Xu X, Delle Fratte R, Collier AC, Melvin AJ, Ho RYY. AIDS 37(14):p 2131-2136, 2023. 10.1097/QAD.0000000000003706   

U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. Susan M. Graham, Douglas Barthold, Brett Hauber, Aaron T. Brah, Enrique Saldarriaga, Ann C. Collier, Rodney J. Y. Ho, the Emory PREFER Team, Vincent C. Marconi, Jane M. Simoni. JIAS Vol 26, Issue 52, July 2023.

Griffin J, Wu Y, Mu Q, Li X, Ho RJY. Pharmaceutics. 2023 Mar 22;15(3):1016. doi: 10.3390/pharmaceutics15031016. PMID: 36986876

MAGAZINE: The Emerging Role of Systems Pharmacology, Long-acting, & Targeted Drug-combination Tech in Making Therapeutic & Health Impact. HO RJY, Perazzolo S, Mu Q, Stephens Z, Euguchi M, Xu X, AAPS News Magazine –  2022 PharmSci 360 Program Highlights – October 2022 AAPS Conference Highlight

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles. Perazzolo S, Shen DD, Ho RJY. J Pharm Sci. 2022 Mar;111(3):825-837. doi: 10.1016/j.xphs.2021.10.009. Epub 2021 Oct 19. PMID: 34673094

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
Perazzolo S, Shireman LM, Shen DD, Ho RJY. J Pharm Sci. 2022 Feb;111(2):529-541. doi: 10.1016/j.xphs.2021.10.007. Epub 2021 Oct 19. PMID: 34673093

The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. Brah AT, Barthold D, Hauber B, Collier AC, Ho RJY, Marconi VC, Simoni JM, Graham SM. AIDS Res Ther. 2022 Feb 25;19(1):13. doi: 10.1186/s12981-022-00435-6. PMID: 35216610

ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models. Zhu L, Mu Q, Yu J, Griffin JI, Xu X, Ho RJY. Pharmaceutics. 2021 Dec 31;14(1):89. doi: 10.3390/pharmaceutics14010089. PMID: 35056985

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Pharmacol Ther. 2022 Aug;236:108108. doi: 10.1016/j.pharmthera.2022.108108. Epub 2022 Jan 6. PMID: 34999182

“Lighten This Burden of Ours”: Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal KenyaSimoni JM, Beima-Sofie K, Wanje G, Mohamed ZH, Tapia K, McClelland RS, Ho RJY, Collier AC, Graham SM. J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211000517. doi: 10.1177/23259582211000517. PMID: 33685272

COVID19 PERSPECTIVE: Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. Perazzolo S, Zhu L, Lin W, Nguyen A, Ho RJY. J Pharm Sci. 2021 Mar;110(3):1002-1017. doi: 10.1016/j.xphs.2020.11.019. Epub 2020 Nov 26. PMID: 33248057

COVID19 COMMENTARY: Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships. Ho RJY. J Pharm Sci. 2021 Feb;110(2):615-618. doi: 10.1016/j.xphs.2020.11.010. Epub 2020 Nov 17. PMID: 33212162

Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules. Yu J, Mu Q, Perazzolo S, Griffin JI, Zhu L, McConnachie LA, Shen DD, Ho RJ. Pharm Res. 2020 Sep 23;37(10):197. doi: 10.1007/s11095-020-02888-8. PMID: 32968837

Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir. Yu J, Yu D, Lane S, McConnachie L, Ho RJY. J Pharm Sci. 2020 Nov;109(11):3480-3489. doi: 10.1016/j.xphs.2020.08.003. Epub 2020 Aug 10. PMID: 32791073

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. Mu Q, Yu J, Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho RJY. PLoS One. 2020 Mar 6;15(3):e0228557. doi: 10.1371/journal.pone.0228557. eCollection 2020. PMID: 32142553

Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101 Perazzolo S, Shireman LM, McConnachie LA, Koehn J, Kinman L, Lee W, Lane S, Collier AC, Shen DD, Ho RJY. J Pharm Sci. 2020 May;109(5):1789-1801. doi: 10.1016/j.xphs.2020.01.016. Epub 2020 Jan 29. PMID: 32006525    December 2020 – J Pharm Sci Hot Pick    

Simoni JM, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Graham SM, Ho R, Collier AC. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. AIDS patient care and STDs. 2019 March;33(3):104-111. PubMed PMID: 30844308; PubMed Central PMCID: PMC6442271.

Gao Y, Kraft JC, Yu D, Ho RJY.  (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy Eur J Pharm Biopharm PMID:  29678735

Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD, Ho RJY. (2018) Three HIV drugs, atazanavir, ritonavir, and tenofovir co-formulated in drug-combination nanoparticles exhibit long-acting and lymphocyte targeting properties in non-human primates J Pharm Sci. PMID:  30121315


Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY. (2018) Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates. AIDS. PMID:  30102655

 Mcconnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY.  (2018) Long-Acting Profile of Four Drugs in One anti-HIV Nanosuspension in Non-Human Primates for Five Weeks Following a Single Subcutaneous Injection.  J Pharm Sci. PMID:  29548975.

Kraft JC, Treuting PM, Ho RJ. (2018) Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution, and retention and enable detailed mapping of lymph vessels, nodes, and abnormalities. J Drug Target. PMID: 29388438.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collier AC, Collins C, Shen DD, Ho RJY. (2018) Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. Journal of Controlled Release. PMID: 29432823.

Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho RJY. (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. J Drug Target. PMID: 29285948.

Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J (2015) Systems Approach to targeted and long-acting HIV/AIDS therapy. Drug Deliv Transl Res. PMID: 26315144.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ (2016) Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond). PMID: 26892323.

Partridge SC, Kurland BF, Liu CL, Ho RJ, Ruddell A (2016) Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles. Sci Rep. PMID: 26497382, PMCID: PMC4620490.

Koehn J, Ding Y, Freeling J, Duan J, Ho RJ. A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2015 Nov;59(11):6682-8. doi: 10.1128/AAC.00869-15. Epub 2015 Jul 27. PubMed PMID: 26248367; PubMed Central PMCID: PMC4604393.

Volkin DB, Hershenson S, Ho RJ, Uchiyama S, Winter G, Carpenter JF. Two decades of publishing excellence in pharmaceutical biotechnology. J Pharm Sci. 2015 Feb;104(2):290-300. doi: 10.1002/jps.24285. Epub 2014 Dec 1. PubMed PMID: 25448882; PubMed Central PMCID: PMC4826475.

Freeling JP, Ho RJ. Antiretroviral nanoparticles: the future is now: authors’ response to editorial comments. AIDS. 2015 Apr 24;29(7):863-4. doi: 10.1097/QAD.0000000000000600. PubMed PMID: 25985411; PubMed Central PMCID: PMC4827420.

Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci. 2015 May;104(5):1815-24. doi: 10.1002/jps.24407. Epub 2015 Mar 9. PubMed PMID: 25753991; PubMed Central PMCID: PMC4830345.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond). 2016;11(5):545-64. doi: 10.2217/nnm.16.1. Epub 2016 Feb 19. PubMed PMID: 26892323; PubMed Central PMCID: PMC4910949.

Ho RJ, Chien J. Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. J Pharm Sci. 2014 Jan;103(1):71-7. doi: 10.1002/jps.23761. Epub 2013 Nov 1. PubMed PMID: 24186148; PubMed Central PMCID: PMC4634700.

Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma. Antimicrob Agents Chemother. 2014 May;58(5):2675-80. doi: 10.1128/AAC.02748-13. Epub 2014 Feb 24. PubMed PMID: 24566184; PubMed Central PMCID: PMC3993260.

Ho RJ, Huang L. Interactions of antigen-sensitized liposomes with immobilized antibody: a homogeneous solid-phase immunoliposome assay. J Immunol. 1985 Jun;134(6):4035-40. PubMed PMID: 3886794.

Xiang L, Chi T, Tang Q, Yang X, Ou M, Chen X, Yu X, Chen J, Ho RJ, Shao J, Jia L. A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget. 2015 Apr 20;6(11):9295-312. PubMed PMID: 25823660; PubMed Central PMCID: PMC4496218.

Freeling J, Ho RJ, Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence. PNAS 2014 June 2; 111(25) E2512-E2513. Doi:10.1073/pnas.1406554111

Freeling J, Koehn J, Cuiling S, Jianguo S, Ho RJ. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS. 2014 November 13;28(17) 2625-2627. doi:10.1097/QAD.0000000000000421

Freeling J, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. 2015; 31(1) 107-113. Doi: 10.1089/aid.2014.0210